Mortality risk among people receiving acute hospital care for hallucinogen use compared with the general population.
Daniel T. Myran, Jennifer Xiao, Nicholas Fabiano, Michael Pugliese, Tyler S Kaster, Joshua D. Rosenblat, Muhammad Ishrat Husain, Jess G. Fiedorowicz, Stanley Wong, Peter Tanuseputro, Marco Solmi
Canadian Medical Association Journal March 2, 2025 DOI: 10.1503/cmaj.241191 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Retrospective cohort study Peer reviewed |
|---|---|
| Sample size | 11,415,713 |
| Population | People aged 15 years and older living in Ontario, Canada |
| Duration | Median 7 (interquartile range 3–11) years follow-up |
| Keywords | Hallucinogen use Psychedelic use Substance use Drug use Hallucinogen misuse Psychedelic misuse Drug abuse Mortality risk Death risk Fatality risk Subsequent mortality Long-term mortality Mortality rate Death rate Public health Population health Health outcomes Health policy Health management Addiction treatment Substance abuse treatment Drug rehabilitation Recovery support Intervention Healthcare support |
| Citations | 8 |
| Key findings | Acute care involving hallucinogens was associated with a 2.6-fold increased all-cause mortality within five years relative to the general population. |
Abstract
Background: Although clinical trials involving psychedelic-assisted psychotherapy have not observed short-term increases in the risk of death, limited data exist on mortality associated with hallucinogen use outside of controlled trial settings. We sought to determine whether people with an emergency department visit or hospital admission involving hallucinogen use were at increased risk of all-cause death compared with the general population and with people with acute care presentations involving other substances.
Methods: We conducted a retrospective cohort study using linked health administrative data on all people aged 15 years and older living in Ontario, Canada, from 2006 to 2022. We compared overall and cause-specific mortality between members of the general population and people with incident acute care (an emergency department visit or hospital admission) involving hallucinogens and other substances.
Results: We included 11 415 713 people; 7953 (0.07%) had incident acute care involving hallucinogens. In a matched analysis with 77 101 people with a median follow-up of 7 (interquartile range 3–11) years, acute care involving hallucinogens was associated with a 2.6-fold (hazard ratio [HR] 2.57, 95% confidence interval [CI] 2.09–3.15) increased all-cause mortality within 5 years (n = 482, absolute risk 6.1%) relative to the general population (n = 460, absolute risk 0.6%). Analyses excluding people with comorbid mental or substance use disorders showed similar elevations in mortality risk for acute care involving hallucinogens relative to the general population (HR 3.25, 95% CI 2.27–4.63). People with acute care involving hallucinogens were at a significantly elevated risk of death by unintentional drug poisoning (HR 2.03, 95% CI 1.02–4.05), suicide (HR 5.23, 95% CI 1.38–19.74), respiratory disease (HR 2.46, 95% CI 1.18–5.11), and cancer (HR 2.88, 95% CI 1.61–5.14) relative to the general population.
Interpretation: Requiring hospital-based care for hallucinogen use was associated with increases in risk of death relative to the general population, particularly from suicide. These findings should be considered in clinical and policy decision-making, given the increasing use of hallucinogens and associated problematic use.
Citations in the library
Cited by 8
- Psilocybin in alcohol use disorder and comorbid depressive symptoms: Results from a feasibility randomized clinical trial Addiction July 24, 2025
- A cross-national comparison of nonmedical and medical use of psychedelic drugs in the international cannabis policy study. International Journal of Drug Policy August 1, 2026
- Psilocybin retail stores in Canada: Changes in availability, commercialization, and geographic distribution Canadian Journal of Public Health March 19, 2026
- Trends in the psychedelic renaissance: applying artificial intelligence to measure media portrayal of psychedelic drugs in the 21st century BJPsych Open February 12, 2026
- Efficacy and risks of psychedelics in treatment of posttraumatic stress disorder: A systematic review American Journal of Health-System Pharmacy March 4, 2026
and 3 more in the library
Cites 10
- Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine November 3, 2022
- Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use Disorder JAMA Psychiatry August 24, 2022
- Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials Journal of Psychopharmacology March 8, 2012
- MDMA‐Assisted Psychotherapy for Treatment of Posttraumatic Stress Disorder: A Systematic Review With Meta‐Analysis The Journal of Clinical Pharmacology October 28, 2021
- Efficacy of psychedelic treatments on depressive symptoms: A meta-analysis Journal of Psychopharmacology May 25, 2020
and 5 more in the library